Edward Samuel
Chief Tech/Sci/R&D Officer at ACHILLES THERAPEUTICS PLC
Profile
Edward Samuel is currently working as the SVP-Technical Operations at Achilles Therapeutics Plc since 2022.
Previously, he worked as the Director-Manufacturing at Cognate BioServices, Inc. from 2015 to 2017 and as the Manager-Cell Therapy Operations at Orchard Therapeutics Plc in 2017.
Dr. Samuel holds a doctorate degree from University College London and a graduate degree from King's College London.
Edward Samuel active positions
| Companies | Position | Start |
|---|---|---|
| ACHILLES THERAPEUTICS PLC | Chief Tech/Sci/R&D Officer | 31/01/2022 |
Former positions of Edward Samuel
| Companies | Position | End |
|---|---|---|
| ORCHARD THERAPEUTICS PLC | Corporate Officer/Principal | 30/11/2017 |
Cognate BioServices, Inc.
 Cognate BioServices, Inc. BiotechnologyHealth Technology Cognate BioServices, Inc. engages in the provision of commercialization services to regenerative medicine, cellular immunotherapy, and cell therapy companies. It offers cGMP clinical and commercial manufacturing; process and assay development and optimization; logistics, supply chain, and manufacturing support services; and clinical, regulatory, and custom services. The company was founded in 2002 and is headquartered in Memphis, TN. | Corporate Officer/Principal | 30/04/2017 |
Training of Edward Samuel
| University College London | Doctorate Degree |
| King's College London | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| ACHILLES THERAPEUTICS PLC | Health Technology |
| Private companies | 2 |
|---|---|
Orchard Therapeutics Plc
 Orchard Therapeutics Plc Pharmaceuticals: MajorHealth Technology Orchard Therapeutics Plc is a biopharmaceutical company, which engages in discovering, acquiring, developing and commercializing gene therapies for patients with rare disorders. The company focuses on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies. Its portfolio includes Strimvelis, a commercial-stage gamma retroviral-based product for the treatment of Adenosine deaminase deficiency (ADA-SCID). The company was founded by Nicolas Koebel and Andrea Spezzi in August 2018 and is headquartered in London, the United Kingdom. | Health Technology |
Cognate BioServices, Inc.
Cognate BioServices, Inc. BiotechnologyHealth Technology Cognate BioServices, Inc. engages in the provision of commercialization services to regenerative medicine, cellular immunotherapy, and cell therapy companies. It offers cGMP clinical and commercial manufacturing; process and assay development and optimization; logistics, supply chain, and manufacturing support services; and clinical, regulatory, and custom services. The company was founded in 2002 and is headquartered in Memphis, TN. | Health Technology |
- Stock Market
- Insiders
- Edward Samuel
